Description
CJC-1295 with DAC Research Peptide
CJC-1295 with DAC is a synthetic modified growth hormone releasing hormone analogue (GHRH 1-29) supplied for controlled laboratory investigation. This compound incorporates a Drug Affinity Complex (DAC) to extend its half-life, a key feature for studies examining sustained physiological effects. Researchers investigate CJC-1295 with DAC to understand its role in modulating the growth hormone axis, allowing for repeatable studies under standardized conditions.
Because of its extended half-life, researchers value CJC-1295 with DAC for exploring prolonged signaling patterns and interaction behavior within the somatotropic axis. This allows for the collection of consistent data over extended observation periods in controlled environments. Studies focus on its unique mechanism involving albumin binding, which differentiates its pharmacokinetic profile from unmodified GHRH analogues, providing insights into peptide stability.
In laboratory settings, CJC-1295 with DAC is handled following standard peptide preparation and safety procedures. It is typically supplied as a lyophilized powder. For reconstitution, bacteriostatic water is recommended. After reconstitution, the solution should be refrigerated at 2-8°C. For extended storage, the lyophilized powder should be stored in cool, dry conditions or frozen at -20°C.
The consistent composition and defined structure of CJC-1295 with DAC contribute to reduced experimental variation, enhancing the reliability of research outcomes. This compound’s suitability for structured research workflows supports long-term laboratory projects focused on endocrine modulation, providing consistent data for comparative analyses across different experimental conditions.
Ongoing research continues to include CJC-1295 with DAC due to its defined sequence and stable behavior. Its suitability for controlled research models makes it a valuable tool for investigating GHRH analogue pharmacokinetics and pharmacodynamics, and for examining sustained regulatory effects on the pituitary gland.
Important Notice: CJC-1295 with DAC 5mg is provided strictly for research use only. This product is not intended for human or animal use, clinical applications, diagnostic procedures, or consumption of any kind. All research must be conducted by qualified professionals in appropriate laboratory environments and in compliance with applicable regulations and guidelines.
Frequently Asked Questions
What is CJC-1295 with DAC?
CJC-1295 with DAC is a synthetic modified growth hormone-releasing hormone (GHRH) analogue, specifically a 29-amino acid peptide derived from GHRH (1-29). It features a Drug Affinity Complex (DAC) moiety, which allows for covalent binding to circulating albumin. This modification is designed to extend its half-life in research models. Its CAS number is 863288-34-0.
How does the DAC component modify CJC-1295?
The Drug Affinity Complex (DAC) component in CJC-1295 with DAC is a non-peptide linker that enables the molecule to reversibly bind to albumin in the bloodstream. This binding mechanism protects the peptide from enzymatic degradation and reduces renal clearance, significantly extending its half-life compared to unmodified GHRH analogues. This allows for sustained exposure in controlled research settings.
What biological systems are studied using CJC-1295 with DAC?
Researchers primarily study CJC-1295 with DAC in the context of the somatotropic axis, focusing on the endocrine system’s regulation of growth hormone (GH) secretion. Studies investigate its effects on the pituitary gland’s somatotroph cells, which are responsible for synthesizing and releasing GH. It is also examined in research models exploring metabolic processes and tissue recovery dynamics.
What is the mechanism of action of CJC-1295 with DAC?
CJC-1295 with DAC acts as a GHRH analogue, binding to and activating GHRH receptors on the somatotroph cells of the anterior pituitary gland. This activation stimulates the pulsatile release of endogenous growth hormone. The DAC modification ensures a prolonged presence in the circulation, leading to a sustained GHRH receptor activation and subsequent growth hormone secretion in research models.
Why is CJC-1295 with DAC of interest in peptide research?
CJC-1295 with DAC is of interest in peptide research primarily due to its extended half-life, which facilitates studies requiring sustained GHRH receptor activation. This allows researchers to investigate the long-term effects of modulated growth hormone release without frequent administration. Its unique pharmacokinetic profile provides a valuable model for examining strategies to enhance peptide stability and bioavailability in controlled settings.
How should CJC-1295 with DAC be stored for research use?
For optimal preservation, CJC-1295 with DAC should be stored as a lyophilized powder in a cool, dry place, protected from light. After reconstitution with bacteriostatic water, the solution should be refrigerated at 2-8°C and used within a specified period. For extended storage of the reconstituted solution, freezing at -20°C is recommended to maintain peptide integrity in research applications.
Reviews
There are no reviews yet.